SCHEMBL4329388

SCHEMBL4329388

CC(=O)Nc1cc(Oc2ccc3c(c2)nc(Nc2ccc(F)c(C(C)(C)C)c2)n3C)ccn1

nearest known ligand 0.78

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
BRAF P15056 20/20 0.78
LCK P06239 3/20 0.73
FYN P06241 2/20 0.73
PDGFRB P09619 2/20 0.73
KIT P10721 2/20 0.73
FLT1 P17948 2/20 0.73
FLT4 P35916 2/20 0.73
KDR P35968 2/20 0.73
SRC P12931 1/20 0.73
RAF1 P04049 4/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4322244 0.93 BRAF (0.79) BRAFLCKFYNPDGFRBKIT
SCHEMBL4339509 0.90 BRAF (0.78) BRAFLCKFYNPDGFRBKIT
SCHEMBL4332840 0.88 BRAF (1.00) BRAFLCKFYNPDGFRBKIT
SCHEMBL4331244 0.87 BRAF (0.81) BRAFLCKFYNPDGFRBKIT
SCHEMBL4323716 0.87 BRAF (0.65) BRAFLCKFYNPDGFRBKIT
SCHEMBL4416702 0.86 BRAF (0.78) BRAFLCKFYNPDGFRBKIT
SCHEMBL4334683 0.86 BRAF (0.83) BRAFLCKFYNPDGFRBKIT
SCHEMBL4325129 0.85 BRAF (0.78) BRAFLCKFYNPDGFRBKIT
SCHEMBL4324914 0.85 BRAF (0.87) BRAFLCKFYNPDGFRBKIT
SCHEMBL4321927 0.85 BRAF (0.77) BRAFLCKFYNPDGFRBKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415382-B2 Substituted benzazoles and methods of their use as inhibitors of RAF Kinase NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2013-04-09 US disclosed
US-8415382-B2 Substituted benzazoles and methods of their use as inhibitors of RAF Kinase NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2013-04-09 US disclosed
US-8415382-B2 Substituted benzazoles and methods of their use as inhibitors of RAF Kinase NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2013-04-09 US disclosed
EP-1682126-B1 SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE NOVARTIS VACCINES & DIAGNOSTIC (US) 2009-07-01 EP disclosed
US-20090035309-A1 Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase NOVARTIS AG 2009-02-05 US disclosed
US-20090035309-A1 Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase NOVARTIS AG 2009-02-05 US disclosed
US-20090035309-A1 Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase NOVARTIS AG 2009-02-05 US disclosed
US-7423150-B2 Substituted benzazoles and methods of their use as inhibitors of Raf kinase NOVARTIS AG (CH) 2008-09-09 US disclosed
US-20050192287-A1 Substituted benzazoles and methods of their use as inhibitors of Raf kinase CHIRON CORPORATION (US) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035309-A1 Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase BRAF, RAF1, ARAF BRAF 1/4885LCK 279/4885FYN 633/4885
US-20050192287-A1 Substituted benzazoles and methods of their use as inhibitors of Raf kinase BRAF, RAF1, ARAF BRAF 1/4885LCK 279/4885FYN 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.